$33.03
1.84% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Dyne Therapeutics Inc Stock price

$33.03
-10.35 23.86% 1M
+6.25 23.34% 6M
+19.73 148.35% YTD
+21.26 180.63% 1Y
+16.40 98.62% 3Y
+9.13 38.20% 5Y
+9.13 38.20% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-0.62 1.84%
ISIN
US26817R1086
Symbol
DYN
Sector
Industry

Key metrics

Market capitalization $3.32b
Enterprise Value $2.56b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 4.27
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-271.08m
Free Cash Flow (TTM) Free Cash Flow $-220.31m
Cash position $778.84m
EPS (TTM) EPS $-3.58
P/E forward negative
Short interest 8.75%
Show more

Is Dyne Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Dyne Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Dyne Therapeutics Inc forecast:

Buy
100%

Financial data from Dyne Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
- -
-
100%
- Direct Costs 1.95 1.95
16% 16%
-
-1.95 -1.95
16% 16%
-
- Selling and Administrative Expenses 46 46
82% 82%
-
- Research and Development Expense 221 221
34% 34%
-
-269 -269
40% 40%
-
- Depreciation and Amortization 1.95 1.95
16% 16%
-
EBIT (Operating Income) EBIT -271 -271
39% 39%
-
Net Profit -258 -258
36% 36%
-

In millions USD.

Don't miss a Thing! We will send you all news about Dyne Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dyne Therapeutics Inc Stock News

Negative
Investors Business Daily
4 days ago
Dyne Therapeutics stock crashed Tuesday after several key executives departed on the heels of what the company calls "unprecedented" in DMD.
Neutral
GlobeNewsWire
5 days ago
- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs -
Neutral
GlobeNewsWire
5 days ago
- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 - - Virtual Investor Event Today at 8:00 a.m. ET -
More Dyne Therapeutics Inc News

Company Profile

Dyne Therapeutics, Inc. engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystroph. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Head office United States
CEO John Cox
Employees 141
Founded 2017
Website www.dyne-tx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today